Inductive Bio develops AI-powered virtual laboratories for drug discovery, specialising in the evaluation and optimisation of small molecule compounds. The company's platform focuses on ADMET properties - a critical set of criteria that determines how a drug is absorbed, distributed, metabolised, excreted, and whether it is toxic. By running millions of in silico experiments, the technology allows chemistry teams to assess ideas at a scale not feasible through traditional wet-lab methods.
At the core of the offering is the Beacon-1 class of AI models, engineered specifically for the heterogeneous data inherent in real-world ADMET research. These models are designed to identify the key molecular drivers of ADMET outcomes and guide compound optimisation. The technology's effectiveness has been demonstrated externally: it won first place in the world's largest ADMET prediction competitions, outperforming more than 370 submissions from leading pharmaceutical and technology companies.
The company operates at the intersection of AI/ML, computational chemistry, and drug discovery, serving the pharmaceutical industry. Its stated objective is to help research teams make faster, better-informed decisions about which chemical compounds to advance in the development pipeline.
